Current Atherosclerosis Reports

, Volume 10, Issue 1, pp 5–10

Clinical trials report

  • Michael Clearfield
Article
  • 20 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Deedwania PC, Carbajal EV: Silent ischemia during daily life is an independent predictor of mortality in stable angina. Circulation 1990, 81:748–756.PubMedGoogle Scholar
  2. 2.
    Andrews TC, Raby K, Barry J, et al.: Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation 1997, 95:324–328.PubMedGoogle Scholar
  3. 3.
    Van Boven AJ, Jukema JW, Zwinderman AH, et al.: Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996, 94:1503–1505.PubMedGoogle Scholar
  4. 4.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared to moderate lipid lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080.PubMedCrossRefGoogle Scholar
  5. 5.
    Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504.PubMedCrossRefGoogle Scholar
  6. 6.
    Stone PH, Lloyd-Jones DM, Kinlay S, et al.: Effect of intensive lipid lowering, with or without antioxidant vitamins, compared with moderate lipid lowering on myocardial ischemia in patients with stable coronary artery disease: the Vascular Basis for Treatment of Myocardial Ischemia Study. Circulation 2005, 111:1747–1755.PubMedCrossRefGoogle Scholar
  7. 7.
    Collins R, Armitage J, Parish S, et al., for the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvstatin in 20,536 high risk individuals: a randomized placebo controlled trial. Lancet 2002, 360:7–22.CrossRefGoogle Scholar
  8. 8.
    Sherpherd J, Blauw GJ, Murphy MB, et al., for the PROSPER study group: Prospective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002, 360:1623–1630.CrossRefGoogle Scholar
  9. 9.
    Deedwania P, Stone PH, Merz CN, et al.: Effects of intensive versus moderate lipid lowering therapy on myocardial ischemia in older patients with coronary heart disease. Results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007, 115:700–707.PubMedCrossRefGoogle Scholar
  10. 10.
    Nissen SE, Nicholls SJ, Sipahi I, et al.: Effect of very high intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006, 295:1556–1565PubMedCrossRefGoogle Scholar
  11. 11.
    Crouse JR III: Thematic review series: patient oriented research; imaging atherosclerosis: state of the art. J Lipid Res 2006, 47:1677–1699.PubMedCrossRefGoogle Scholar
  12. 12.
    Oren A, Vos LE, Uiterwaal CS, et al.: Cardiovascular risk factors and increased carotid intima medica thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (AYRA) Study. Arch Int Med 2003, 163:1787–1792.CrossRefGoogle Scholar
  13. 13.
    Espeland MA, O’Leary DH, Terry JG, et al.: Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005, 6:3.PubMedCrossRefGoogle Scholar
  14. 14.
    Bots ML: Carotid intima medial thickness as a surrogate marker for cardiovascular disease in intervention studies. Curr Med Res Opin 2006, 22:2181–2190.PubMedCrossRefGoogle Scholar
  15. 15.
    Kent SM, Taylor AJ: Usefulness of lowering LDL-C to <70 mg/dl and usefulness of C-reactive protein in patient selection. Am J Cardiol 2003, 92:1224–1227.PubMedCrossRefGoogle Scholar
  16. 16.
    Nissen SE, Tuzcu EM, Schoenhagen P, et al.: Effect of intensive compared to moderate lipid lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004, 291:1071–1080.PubMedCrossRefGoogle Scholar
  17. 17.
    Brown MS, Goldstein JL: Lowering LDL-Not only how low, but how long? Science 2006, 311:1721–1723.PubMedCrossRefGoogle Scholar
  18. 18.
    Gordon DJ, Probstfield JL, Garrison RJ et al.: High density lipoprotein cholesterol and cardiovascular disease. Circulation 1989, 79:8–15.PubMedGoogle Scholar
  19. 19.
    Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.Google Scholar
  20. 20.
    Brown BG, Zhao XQ, Chait A, et al.: Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345:1583–1592.PubMedCrossRefGoogle Scholar
  21. 21.
    Taylor AJ, Sullenberger LE, Lee HJ, et al.: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double blind, placebo controlled study of extended release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110:3512–3517.PubMedCrossRefGoogle Scholar
  22. 22.
    Inazu A, Brown ML, Hesler CB, et al.: Increased HDL levels caused by a common cholesterol ester transfer protein gene mutation. N Engl J Med 1990, 323:1234–1238.PubMedCrossRefGoogle Scholar
  23. 23.
    Brousseau ME, Schaefer EJ, Wolfe ML, et al.: Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol. N Engl J Med 2004, 350:1505–1515.PubMedCrossRefGoogle Scholar
  24. 24.
    Nissen SE, Tardif JC, Nicholls SJ, et al., for the ILLUSTRATE Investigators: Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007, 356:1304–1316.PubMedCrossRefGoogle Scholar
  25. 25.
    Tall AR, Yvan-Charet L, Wang N: The failure of torcetrapib: was it the molecule or the mechanism? Atherioscler Thromb Vasc Biol 2007, 27:257–260.CrossRefGoogle Scholar
  26. 26.
    Kastelein JP, van Leuven SI, Burgess L, et al., for the RADIANCE 1 Investigators: Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007, 356:1620–1630.PubMedCrossRefGoogle Scholar
  27. 27.
    Mosca L, Appel LJ, Benjamin EJ, et al.: Evidence based guidelines for cardiovascular disease prevention in women. Circulation 2004, 109:672–693.PubMedCrossRefGoogle Scholar
  28. 28.
    Hirano K, Yamashita S, Nakajima N, et al.: Genetic cholesteryl ester transfer protein deficiency is extememly frequent in Omagari area of Japan: marked hyperalphalioproteinemia caused by CETP gene mutation is not associated with longevity. Atheroscler Thromb Vasc Biol 1997, 17:1053–1059.Google Scholar
  29. 29.
    Agerholm-Larsen B, Nordestgaard BG, Steffensen R, et al.: Elevated HDL-C is a risk factor for ischemic heart disease in white women when caused by a common mutation in cholesterol ester transfer protein gene. Circulation 2000, 101:1907–1912.PubMedGoogle Scholar
  30. 30.
    Nissen SE, Tsunoda T, Tuzcu EM, et al.: Effect of recombinant ApoA-1 Milano on coronary atherosclerosis in patients with acute coronary syndrome. JAMA 2003, 2292–2300.Google Scholar
  31. 31.
    Tardif JC, Gregoire J, Allier P, et al.: Effects of reconstituted HDL infusions on coronary atherosclerosis. JAMA 2007, 297:1675–1682.PubMedCrossRefGoogle Scholar
  32. 32.
    Nicholls SJ, Tuzcu EM, Sipahi I, et al.: Statins, HDL-C, and regression of coronary atherosclerosis. JAMA 2007, 297:499–508.PubMedCrossRefGoogle Scholar
  33. 33.
    Kuivenhoven JA, de Grooth GJ, Kawamura H, et al.: Effectiveness of inhibition of cholesterol ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005, 95:1085–1088.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Michael Clearfield

There are no affiliations available

Personalised recommendations